[Acalabrutinib (pretreated chronic lymphocytic leukaemia) - Second Addendum to Commission A20-105]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004500
German
Original Title:
Acalabrutinib (vorbehandelte chronische lymphatische Leukaemie) - 2. Addendum zum Auftrag A20-105
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/g21-13.html
Year Published:
2021
URL for published report:
https://www.iqwig.de/download/g21-13_acalabrutinib_addendum-zum-auftrag-a20-105_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Leukemia, Lymphocytic, Chronic, B-Cell
- Antineoplastic Combined Chemotherapy Protocols
- Antineoplastic Agents
- Tyrosine Kinase Inhibitors
Keywords
- Acalabrutinib
- Leukemia - Lymphocytic - Chronic - B-Cell
- Health Care Costs
- Epidemiology
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.